Fat Transfer Provides Alternative to Breast Implants
After Brava® Pre-Expansion, Patients' Own Fat Can Be Used to Increase Breast Size
Arlington Heights, Ill. - Preoperative expansion of the breast followed by injection of the patient's own fat provides a safe and effective alternative to implant surgery for breast augmentation, reports a study in the May issue of Plastic and Reconstructive Surgery®, the official medical journal of the American Society of Plastic Surgeons (ASPS).
The technique-which includes using a special suction-pump bra device for a few weeks before surgery to "pre-expand" the breasts-provides greater augmentation than fat transfer alone, according to the new report. The lead author was ASPS Member Surgeon Roger K. Khouri, MD of Florida International University and Miami Breast Center, Key Biscayne, Fla.
Pre-Expansion Provides Better Results with Injected Fat
The technique is an adaptation of the increasingly popular autologous (patient's own) fat transplantation technique. In this approach, fat obtained by liposuction from one part of the body-for example, the thighs-is transferred for use in breast augmentation and reshaping.
In the technique used by Dr. Khouri and colleagues, the patient first undergoes several weeks of "pre-expansion" treatment. This is done using Dr. Khouri's invention, Brava®, a bra-like device that uses gentle negative pressure (a vacuum) to gradually expand the breast. Brava pre-expansion provides extra room in the breast, along with a "fibrovascular scaffold" that the transplanted fat cells can occupy. The patient also wears Brava for a week or so after fat cell injection.
The study presents the results of the new technique in 81 women who desired breast augmentation but didn't want implants. All but ten patients used Brava as instructed before the fat transfer procedure.
One year after surgery, breast volume was increased by an average of about 230 cc (about eight fluid ounces) in women undergoing the Brava procedure. That was significantly greater than the 130 cc average reported by previous studies using fat transplantation alone without pre-expansion.
A Less-Invasive Alternative for Breast Augmentation?
The difference was explained by increased survival of transplanted fat cells after pre-expansion: about 80 percent, as measured by MRI scans before and after surgery. This compared to about 55 percent fat cell survival without pre-expansion.
There were no major complications. Sixteen percent of women had areas of fat cell necrosis (cell death), which was harmless and easily detected on mammograms.
While the idea of breast fat transfer is not new, it has seen a resurgence in recent years, with several groups of plastic surgery researchers reporting successful results. However, relatively low survival of the transplanted fat cells has been a limiting factor. Without pre-expansion, there is simply not enough room within the breast for the transplanted fat cells to survive and thrive.
Using Brava before and after fat transplantation provides more optimal conditions for successful fat transfer, Dr. Khouri and colleagues believe. Another group of plastic surgeons recently reported similarly good results with Brava pre-expansion (see Plastic and Reconstructive Surgery, June, 2011).
With recommended use of the Brava device before fat transfer, at least some women can expect to double their original breast size in a single, outpatient procedure with no incision, Dr. Khouri and coauthors write. While further research and experience are needed, the researchers think their study "establishes a benchmark and a platform for further potential improvements."
Plastic and Reconstructive Surgery® is published by Lippincott Williams & Wilkins, part of Wolters Kluwer Health.
About Plastic and Reconstructive Surgery
For more than 70 years, Plastic and Reconstructive Surgery® has been the one consistently excellent reference for every specialist who uses plastic surgery techniques or works in conjunction with a plastic surgeon. The official journal of the American Society of Plastic Surgeons, Plastic and Reconstructive Surgery® brings subscribers up-to-the-minute reports on the latest techniques and follow-up for all areas of plastic and reconstructive surgery, including breast reconstruction, experimental studies, maxillofacial reconstruction, hand and microsurgery, burn repair and cosmetic surgery, as well as news on medico-legal issues.
The American Society of Plastic Surgeons (ASPS) is the largest organization of board-certified plastic surgeons in the world. Representing more than 7,000 physician members, the society is recognized as a leading authority and information source on cosmetic and reconstructive plastic surgery. ASPS comprises more than 94 percent of all board-certified plastic surgeons in the United States. Founded in 1931, the society represents physicians certified by The American Board of Plastic Surgery or The Royal College of Physicians and Surgeons of Canada.
About Wolters Kluwer
Wolters Kluwer (WKL) is a global leader in professional information, software solutions, and services for the clinicians, nurses, accountants, lawyers, and tax, finance, audit, risk, compliance, and regulatory sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with advanced technology and services.
Wolters Kluwer reported 2019 annual revenues of €4.6 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 19,000 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.
Wolters Kluwer provides trusted clinical technology and evidence-based solutions that engage clinicians, patients, researchers and students in effective decision-making and outcomes across healthcare. We support clinical effectiveness, learning and research, clinical surveillance and compliance, as well as data solutions. For more information about our solutions, visit https://www.wolterskluwer.com/en/health and follow us on LinkedIn and Twitter @WKHealth.